Why the study?
Does intravenous epoprostenol reduce restenosis at six months and inhibit platelet aggregation in patients undergoing successful coronary angioplasty?
Does intravenous epoprostenol reduce restenosis at six months and inhibit platelet aggregation in patients undergoing successful coronary angioplasty?
A short-term infusion of epoprostenol at a dose designed to limit side effects failed to inhibit platelet aggregation or significantly reduce the six-month restenosis rate after coronary angioplasty.
Answers are grounded in this paper and cite their sources.
Epoprostenol does not reduce restenosis after coronary angioplasty; challenges short-term platelet inhibition as an effective preventive strategy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gershlick et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: